FHTX

+ Watchlist + Portfolio

Foghorn Therapeutics Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $7.06
52-Week Range: $3.27 – $7.61
Market Cap: $416.29M
P/E (TTM): —
EPS (TTM): -0.99
Dividend Yield: —

Advanced Metrics

Price/Book: —
PEG Ratio: —
Return on Equity: —
Return on Assets: -19.92%
Gross Margin: -114.57%
Operating Margin: -54.78%
Profit Margin: -175.78%
Current Ratio: 3.36
Debt/Equity: —
Total Debt: $43.10M
Free Cash Flow: $-51.95M
Revenue Growth: 112.70%
Earnings Growth: —
Enterprise Value: $294.78M

FHTX Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$19.23M	$34.16M	$22.60M	$30.91M
Research & Development	$105.62M	$109.69M	$94.53M	$85.47M
Selling, General & Admin	$30.75M	$32.37M	$28.36M	$27.55M
Operating Expenses	$136.37M	$142.06M	$122.89M	$113.02M
Operating Income	-$117.14M	-$107.91M	-$100.28M	-$82.11M
EBITDA	-$113.82M	-$104.45M	-$97.17M	-$78.78M
Pretax Income	-$108.88M	-$94.20M	-$86.62M	-$74.28M
Income Tax	$0.00	$4.23M	$0.00	—
Net Income	-$108.88M	-$98.43M	-$86.62M	-$74.28M
Diluted EPS	-2.62	-2.34	-1.58	-1.18
Diluted Shares	41.59M	41.97M	54.90M	62.98M

FHTX Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$52.21M	$80.34M	$55.45M	$80.88M
Receivables	$0.00	—	—	—
Current Assets	$351.40M	$240.18M	$249.60M	$163.24M
Total Assets	$404.88M	$285.92M	$283.98M	$198.10M
Current Liabilities	$55.20M	$58.44M	$66.99M	$59.74M
Total Debt	$51.51M	$45.07M	$37.13M	$41.27M
Total Liabilities	$404.77M	$363.11M	$329.51M	$306.60M
Retained Earnings	-$373.14M	-$471.56M	-$558.18M	-$632.47M
Shareholders' Equity	$112.00K	-$77.19M	-$45.53M	-$108.50M
Working Capital	$296.19M	$181.75M	$182.61M	$103.50M

FHTX Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	$193.61M	-$118.11M	-$100.41M	-$86.10M
Capital Expenditure	-$1.21M	-$1.22M	-$906.00K	-$50.00K
Free Cash Flow	$192.40M	-$119.33M	-$101.31M	-$86.15M
Depreciation & Amortisation	$3.32M	$3.45M	$3.12M	$3.33M
Stock-Based Compensation	$14.34M	$16.19M	$11.89M	$10.40M
Investing Cash Flow	-$244.32M	$144.45M	-$29.90M	$112.04M
Financing Cash Flow	$1.76M	$1.78M	$105.43M	$1.02M
Net Change in Cash	-$48.95M	$28.12M	-$24.88M	$26.96M

FHTX Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$5.95M	$7.56M	$8.15M	$9.25M	$3.27M
Research & Development	$21.63M	$21.79M	$20.00M	$22.05M	$18.26M
Selling, General & Admin	$7.24M	$6.86M	$6.65M	$6.80M	$6.58M
Operating Expenses	$28.86M	$28.65M	$26.65M	$28.84M	$24.84M
Operating Income	-$22.91M	-$21.10M	-$18.50M	-$19.60M	-$21.57M
EBITDA	-$22.09M	-$20.25M	-$17.65M	-$18.79M	-$21.34M
Pretax Income	-$18.83M	-$17.94M	-$15.85M	-$21.66M	-$19.88M
Net Income	-$18.83M	-$17.94M	-$15.85M	-$21.66M	-$19.88M
Diluted EPS	-0.30	-0.28	-0.25	—	-0.29
Diluted Shares	62.85M	62.98M	63.03M	—	69.54M

FHTX Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$61.03M	$72.57M	$89.33M	$80.88M	$87.66M
Current Assets	$225.42M	$203.84M	$184.12M	$163.24M	$188.06M
Total Assets	$258.69M	$226.24M	$204.96M	$198.10M	$222.17M
Current Liabilities	$71.31M	$77.79M	$85.09M	$59.74M	$64.40M
Total Debt	$34.85M	$23.70M	$22.53M	$41.27M	$41.99M
Total Liabilities	$320.34M	$302.89M	$294.62M	$306.60M	$298.57M
Retained Earnings	-$577.02M	-$594.95M	-$610.80M	-$632.47M	-$652.34M
Shareholders' Equity	-$61.65M	-$76.66M	-$89.66M	-$108.50M	-$76.41M
Working Capital	$154.11M	$126.06M	$99.03M	$103.50M	$123.66M

FHTX Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$23.97M	-$21.00M	-$18.86M	-$22.27M	-$25.27M
Capital Expenditure	-$28.00K	-$22.00K	—	—	—
Free Cash Flow	-$24.00M	-$21.02M	-$18.86M	-$22.27M	-$25.27M
Depreciation & Amortisation	$827.00K	$851.00K	$852.00K	$802.00K	$238.00K
Stock-Based Compensation	$2.69M	$2.73M	$2.73M	$2.24M	$2.38M
Investing Cash Flow	$29.40M	$33.83M	$35.57M	$13.23M	-$17.72M
Financing Cash Flow	$139.00K	$254.00K	$49.00K	$581.00K	$49.77M
Net Change in Cash	$5.57M	$13.09M	$16.76M	-$8.46M	$6.79M

Market Snapshot

About

Foghorn Therapeutics Inc. is a clinical-stage biotechnology company focused on developing medicines targeting genetically determined dependencies within the chromatin regulatory system. The company's proprietary Gene Traffic Control platform identifies and validates novel drug targets within chromatin regulatory mechanisms. Foghorn's pipeline includes oncology programs aimed at treating cancers with specific genetic alterations. The company collaborates with leading academic institutions and maintains strategic partnerships to advance its therapeutic candidates. Foghorn focuses on precision medicine approaches where patient selection is guided by genetic biomarkers. The firm is based in Cambridge, Massachusetts, within the biotech cluster.